A recent case report from the Canadian Medical Association Journal provides practical insights for clinicians managing acute ischemic stroke. The successful treatment of a 68-year-old patient with tenecteplase underscores three key clinical considerations: effective thrombolysis was achieved, simplified single-bolus dosing streamlined treatment administration, and growing evidence supports this agent as a viable alteplase alternative.
Tenecteplase offers distinct operational advantages in acute stroke settings. Its longer half-life and superior fibrin specificity reduce the complexity of treatment protocols, while single-bolus administration saves critical time in emergency departments where speed directly influences neurological outcomes.
For practitioners evaluating thrombolytic options, recent randomized controlled trials demonstrating non-inferiority to alteplase provide additional confidence. This case report contributes to an expanding evidence base that may reshape clinical decision-making around acute stroke thrombolysis. Understanding tenecteplase’s practical benefits positions clinicians to optimize patient care delivery in time-critical cerebrovascular emergencies. Read the full article on GMJ Newsroom.
Was this article helpful?
